Use of topical anti-inflammatory and antineoplastic agents in the treatment of young-aged actinic cheilitis: A systematic review

Cristianne Kalinne Santos Medeiros,Glória Maria de França,Jabes Gennedyr da Cruz Lima,Juliana Campos Pinheiro,Dennys Ramon de Melo Fernandes Almeida,Pedro Paulo de Andrade Santos
DOI: https://doi.org/10.1111/jocd.14118
Abstract:Introduction: Several treatments have been used to reduce inflammation and to reverse epithelial alterations in actinic cheilitis (AC). Aim: A systematic review was conducted to analyze the potential of topical treatments for remission and clinical improvement of AC as well as patient acceptability. Methods: A systematic review of clinical trials was conducted following the PICO strategy to answer the following question: Are topical anti-inflammatory and antineoplastic agents effective in the treatment of actinic cheilitis? The quality of the studies was assessed by ROB-2, and the certainty of evidence was rated by GRADE guidelines. Results: Eight clinical trials were selected, including four that investigated the use of anti-inflammatory drugs and four use of antineoplastic agents. The use of 3% diclofenac sodium was associated with partial remission of AC, while 5% imiquimod and ingenol mebutate promoted complete remission. Furthermore, 5% fluorouracil was the drug most associated with complications during treatment. Diclofenac sodium (3%) and fludroxycortide showed the best acceptance by the patients, especially in terms of symptom relief and comfort provided. Conclusion: The anti-inflammatory and antineoplastic agents analyzed largely provided good clinical outcomes, with evidence of remission of AC lesions, development of few local adverse reactions during treatment, and good patient adherence.
What problem does this paper attempt to address?